

Target Healthcare REIT

Income growth and growing NAV

Target has published its quarterly NAV and dividend update. NAV total return was 3.0% in the quarter including dividends paid of 1.570p. With investor interest in modern, purpose-built care homes remaining strong the portfolio valuation increased further. While this is positive for NAV, it also highlights the strong competition for quality assets in the market. Despite the competitive market conditions, as previously indicated the managers have identified a number of acquisition opportunities that meet its qualitative and financial hurdles on which due diligence is progressing.

Year end	Revenue (£m)	EPRA net earnings* (£m)	EPRA EPS* (p)	EPRA NAV/ share (p)	DPS (p)	Price/EPRA NAV/share (x)	Yield (%)
06/16	16.9	8.1	4.7	100.6	6.18	1.17	5.3
06/17	23.6	12.2	4.8	101.9	6.28	1.15	5.4
06/18e	28.0	15.8	6.3	104.1	6.45	1.13	5.5
06/19e	30.5	17.5	6.9	106.5	6.58	1.10	5.6

Note: *EPRA earnings exclude revaluation movements, non-cash income arising from the accounting treatment of lease incentives and guaranteed rent review uplifts, and the costs of acquisitions.

Income in line; lifting NAV forecast

In the three months to 30 September 2017, Target's EPRA NAV per share increased by 1.4p to 103.3p per share after the payment of 1.570p per share in dividends during the period. A 1.6125p DPS has been declared for the quarter under review. Passing rent increased 3.7%: 3.1% from previously disclosed acquisitions and 0.6% from rent reviews. The external portfolio valuation saw the EPRA net initial yield (NIY) tighten to 6.69% from 6.75% in June, combining with rent increases to generate 1.8p per share in property revaluation gains. Our only forecast change is to increase our assumed revaluation gains for the year from £6.0m to £9.0m with the balance of the year benefitting from an assumed 2% pa increase in rents and no further change in NIY. This adds 1.2p to our EPRA NAV per share forecasts.

Strong pipeline of growth opportunities

As discussed at length in our recent <u>update note</u>, Target seeks further portfolio growth, capturing the positive spread between rental income and funding costs, generating operational efficiencies, and further diversifying the portfolio. The investment manager continues to perform due diligence on a strong pipeline of opportunities and while it is not certain that all of these will proceed in aggregate they are higher than we have forecast. The scale of the opportunities is such that additional equity and debt capital support, not in our forecasts, may be required.

Valuation: Long-term income visibility

The mid-teens premium to EPRA NAV is supported by an attractive 5.5% prospective dividend yield, with our estimated cover increasing to 97% in FY18 and 106% in FY19. The long-term need for care home provision is clear, providing a strong opportunity for investors in modern, purpose-built facilities, such as Target, in combination with efficient, well managed, and financially sound operators.

NAV & dividend update

Real estate

447 2En

9 November 2017

Price	117.25p
Market cap	£296m
Net debt (£m) at 30 June 2017	28.9
Net LTV at 30 June 2017	10.5%
Shares in issue	252.2m
Free float	90%
Code	THRL
Primary exchange	LSE
Secondary exchange	N/A

Share price performance



Business description

Target Healthcare REIT invests in modern, purpose-built residential care homes in the UK let on long leases to high-quality care providers. It selects assets according to local demographics and intends to pay increasing dividends underpinned by structural growth in demand for care.

Next events

Q2 NAV and portfolio	Expected January 2018
undate	

Analysts

Martyn King +44 (0)20 3077 5745 Andrew Mitchell +44 (0)20 3681 2500

financials@edisongroup.com

Edison profile page

Target Healthcare REIT is a research client of Edison Investment Research Limited



/ear to 30 June (£000s)	2014	2015	2016	2017	2018e	2019
NCOME STATEMENT						
Rent revenue Movement in lease incentive or rent review	3,817 1,547	9,898 3,760	12,677 4,136	17,760 5,127	22,449	24,94 5,41
Rental income	5,364	13,658	16,813	22,887	5,414 27,863	30,35
Other income	0,304	66	61	671	100	10
Total revenue	5,364	13,724	16,874	23,558	27,963	30,45
Gains/(losses) on revaluation	(2,233)	(839)	425	2,211	1,279	(27
Cost of corporate acquisitions	0	(174)	(998)	(626)	(688)	(6
Total income	3,131	12,711	16,301	25,143	28,555	30,12
Management fee	(648)	(1,524)	(2,654)	(3,758)	(3,739)	(3,79
Other expenses Total expenditure	(780) (1,428)	(880) (2,404)	(992) (3,646)	(1,236) (4,994)	(1,400)	(1,60 (5,39
Profit before finance and tax	1,703	10,307	12,655	20,149	(5,139) 23,416	24,72
Net finance cost	190	(716)	(929)	(808)	(1,622)	(2,12
Profit before taxation	1,893	9,591	11,726	19,341	21,794	22,5
Tax	(4)	(39)	(24)	(219)	0	,
Profit for the year	1,889	9,552	11,702	19,122	21,794	22,5
Average number of shares in issue (m)	105.2	119.2	171.7	252.2	252.2	252
FRS earnings	1,889	9,552	11,702	19,122	21,794	22,5
Adjusted for rent arising from recognising	(1,547)	(3,760)	(4,136)	(5,127)	(5,414)	(5,41
guaranteed rent review uplifts + lease incentives Adjusted for valuation changes	2,233	839	(425)	(2,211)	(1,279)	2
Adjusted for corporate acquisitions	2,233	174	998	420	688	
EPRA earnings	2,575	6,805	8,139	12,204	15,788	17,5
Adjustment for performance fee	150	466	871	997	935	9
Group adjusted EPRA earnings	2,725	7,271	9,010	13,201	16,723	18,4
FRS EPS (p)	1.80	8.02	6.81	7.58	8.64	8.
EPRA EPS (p)	2.45	5.71	4.74	4.84	6.26	6.9
Adjusted EPS (p)	2.59	6.10	5.25	5.23	6.63	7.
Dividend per share (declared) BALANCE SHEET	6.00	6.12	6.18	6.28	6.45	6.
nvestment properties	81,422	138,164	200,720	266,219	324,093	328,9
Frade and other receivables	01,422	2,530	3,742	3,988	4,495	4,7
Non-current assets	81,422	140,694	204,462	270,207	328,588	333,7
Frade and other receivables	6,524	6,457	13,222	25,629	24,261	29,6
Cash and equivalents	17,125	29,159	65,107	10,410	4,186	4,8
Current assets	23,649	35,616	78,329	36,039	28,447	34,5
Bank loan	(11,764)	(30,865)	(20,449)	(39,331)	(84,487)	(89,64
Other non-current liabilities	(11.764)	(2,530) (33,395)	(4,058) (24,507)	(3,997) (43,328)	(3,997) (88,484)	(3,99)
Non-current liabilities Frade and other payables	(11,764) (3,089)	(3,623)	(5,002)	(5,981)	(5,981)	(93,04
Current Liabilities	(3,089)	(3,623)	(5,002)	(5,981)	(5,981)	(5,98
Net assets	90,218	139,292	253,282	256,937	262,570	268,6
Period end shares (m)	95.2	142.3	252.2	252.2	252.2	252
FRS NAV per ordinary share	94.7	97.9	100.4	101.9	104.1	106
PRA NAV per share	94.7	97.9	100.6	101.9	104.1	106
CASH FLOW	4 000	0.504	44 700	10.011	04 704	00.5
Profit before tax	1,893	9,591	11,726	19,341	21,794	22,5
Adjusted for Net interest payable	(190)	716	929	808	1,622	2,1
Revaluation gains on property portfolio	686	(2,921)	(4,787)	(7,339)	(6,695)	(5,14
Cost of corporate acquisitions	000	(2,321)	(4,707)	626	688	(0,1-
Change in receivables/payables	783	695	1,038	(9,042)	6,275	(25
Net interest paid	161	(514)	(681)	(615)	(1,466)	(1,96
ax paid	0	(47)	(164)	(543)	Ó	
Net cash flow from operating activities	3,333	7,520	8,061	3,236	22,217	17,4
Purchase of investment properties	(51,894)	(51,736)	(34,833)	(37,698)	(29,095)	(2,64
Acquisition of subsidiaries Net cash flow from investing activities	(51.904)	(5,845)	(27,091)	(25,552)	(28,188)	(2,56
ssue of ordinary share capital (net of expenses)	(51,894) 44,520	(57,581) 46,644	(61,924) 97,501	(63,250)	(57,283) 0	(5,20
Sale of shares from treasury	44,520	40,044	14,799	0	0	
Repayment)/drawdown of loans	8,646	22,525	(12,808)	20,906	45,000	5,0
Dividends paid	(4,364)	(7,074)	(9,681)	(15,589)	(16,158)	(16,5
Net cash flow from financing activities	48,802	62,095	89,811	5,317	28,842	(11,5
let change in cash and equivalents	241	12,034	35,948	(54,697)	(6,224)	6
Opening cash and equivalents	16,884	17,125	29,159	65,107	10,410	4,1
Closing cash and equivalents	17,125	29,159	65,107	10,410	4,186	4,8
Debt	(11,764)	(30,865)	(20,449)	(39,331)	(84,487)	(89,64
Net cash/(debt)	5,361	(1,706)	44,658	(28,921)	(80,301)	(84,75 23.8



Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholes ale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2017 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Target Healthcare REIT and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this resport. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research and y not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities and Exchange Commission. Edison used to the publishers' exclusion of investment adviser under Section 202(a)(11) of the Investment Advisers Act 2008 (FAA) (as described in the operation of the provide personalised advice. We publish information reflects our sincere opinions. The information that we provide or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) (and the provides of the Edison Securities and the information provide by a subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this